Summit Therapeutics Inc.

12/28/2025 | Press release | Archived content

Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1–positive non-small cell lung cancer in the HARMONi–2 study

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Summit Therapeutics Inc. published this content on December 28, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 21, 2026 at 22:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]